MRNA
NASDAQ · Biotechnology
Moderna Inc
$54.35
+5.81 (+11.97%)
MRNA News9 articles
Moderna Jumps 10% on Hantavirus Vaccine Push as Cruise Ship Outbreak Revives mRNA Hopes
Moderna shares rose 10% on Friday after the company revealed early-stage work on a hantavirus vaccine, spurred by a deadly Andes virus outbreak on the MV Hondius cruise ship.
Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.
Moderna Tops Q1 Revenue Forecast on International Covid Vaccine Sales, Hit by $900M Charge
Moderna's Q1 revenue surged to $389M on international Covid vaccine sales, but a $900M patent charge pushed net loss to $1.34B. Shares fell 2.7%.
GSK Stock Dips on Ex-Dividend Date and Arexvy Vaccine Data Release
GSK shares declined 0.4% in early London trading, influenced by the stock going ex-dividend and the release of new real-world effectiveness data for its respiratory syncytial virus vaccine Arexvy.
Healthcare ETF Rises on Dexcom, Moderna Earnings; Markets Eye Holiday
Healthcare stocks advanced Friday, with the XLV ETF rising 1.1% as Dexcom and Moderna posted strong quarterly results. U.S. markets are closed Monday for the Presidents Day holiday.
Moderna Shares Rise on Q4 Beat, Flu Vaccine Faces FDA Hurdle
Moderna shares advanced roughly 5% late Friday after reporting better-than-expected Q4 revenue. The company reaffirmed its 2026 growth targets despite an FDA setback for its seasonal flu vaccine.
Dow Futures Edge Higher Ahead of Key Economic Data Releases
Dow Jones futures advanced slightly Tuesday as investors await retail sales figures, with payroll and inflation reports due later this week. Tech stocks led Monday's market recovery.
GSK Nears 52-Week Peak on COPD Drug Approval and U.S. Pricing Developments
GSK shares advanced 0.6% in London trading, approaching a 52-week high following EU approval for Nucala in COPD and amid U.S. drug discount initiatives. Insider trading activity and the upcoming ex-dividend date remain in focus.